[HTML][HTML] The gut–liver axis in chronic liver disease: A macrophage perspective
K De Muynck, B Vanderborght, H Van Vlierberghe… - Cells, 2021 - mdpi.com
Chronic liver disease (CLD) is a growing health concern which accounts for two million
deaths per year. Obesity, alcohol overconsumption, and progressive cholestasis are …
deaths per year. Obesity, alcohol overconsumption, and progressive cholestasis are …
[HTML][HTML] A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans
FJ Caballero-Camino, PM Rodrigues, F Wångsell… - Hepatology, 2023 - journals.lww.com
Abstract Background and Aims: Cholestasis is characterized by intrahepatic accumulation of
bile constituents, including bile acids (BAs), which promote liver damage. The apical sodium …
bile constituents, including bile acids (BAs), which promote liver damage. The apical sodium …
[HTML][HTML] Research progress on rodent models and its mechanisms of liver injury
J Mao, L Tan, C Tian, W Wang, H Zhang, Z Zhu, Y Li - Life Sciences, 2023 - Elsevier
The liver is the most important organ for biological transformation in the body and is crucial
for maintaining the body's vital activities. Liver injury is a serious pathological condition that …
for maintaining the body's vital activities. Liver injury is a serious pathological condition that …
Discovery of the first subnanomolar PPARα/δ dual agonist for the treatment of cholestatic liver diseases
Z Feng, J Xiang, G Sun, H Liu, Y Wang… - Journal of Medicinal …, 2023 - ACS Publications
Peroxisome proliferator-activator receptors α/δ (PPARα/δ) are considered as potential drug
targets for cholestatic liver diseases (CLD) via ameliorating hepatic cholestasis …
targets for cholestatic liver diseases (CLD) via ameliorating hepatic cholestasis …
A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut–liver axis
Y Xiao, Y Wang, Y Liu, W Wang, X Tian… - Liver …, 2021 - Wiley Online Library
Abstract Background & Aims Tropifexor (TXR) is a novel nonbile acid that acts as an agonist
of farnesoid X receptor (FXR). TXR is currently in Phase 2 trials for the treatment of non …
of farnesoid X receptor (FXR). TXR is currently in Phase 2 trials for the treatment of non …
[HTML][HTML] Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence …
J van Ertvelde, A Verhoeven, A Maerten… - Journal of Biomedical …, 2023 - Elsevier
Background Adverse outcome pathway (AOP) networks are versatile tools in toxicology and
risk assessment that capture and visualize mechanisms driving toxicity originating from …
risk assessment that capture and visualize mechanisms driving toxicity originating from …
[HTML][HTML] Targeted bile acid profiles reveal the liver injury amelioration of Da-Chai-Hu decoction against ANIT-and BDL-induced cholestasis
YH Zhou, YZ Zhou, YF Li, W Sun, ZL Wang… - Frontiers in …, 2022 - frontiersin.org
Multiple types of liver diseases, particularly cholestatic liver diseases (CSLDs) and biliary
diseases, can disturb bile acid (BA) secretion; however, BA accumulation is currently seen …
diseases, can disturb bile acid (BA) secretion; however, BA accumulation is currently seen …
[HTML][HTML] Inhibition of CBP/β‐catenin signaling ameliorated fibrosis in cholestatic liver disease
M Kimura, K Nishikawa, Y Osawa… - Hepatology …, 2022 - journals.lww.com
Chronic cholestatic liver diseases are characterized by injury of the bile ducts and
hepatocytes caused by accumulated bile acids (BAs) and inflammation. Wnt/β‐catenin …
hepatocytes caused by accumulated bile acids (BAs) and inflammation. Wnt/β‐catenin …
[HTML][HTML] Kupffer cells contested as early drivers in the pathogenesis of primary sclerosing cholangitis
K De Muynck, B Vanderborght, FF De Ponti… - The American Journal of …, 2023 - Elsevier
Primary sclerosing cholangitis (PSC) is an idiopathic chronic immune-mediated cholestatic
liver disease characterized by fibro-inflammatory bile duct strictures, progressive …
liver disease characterized by fibro-inflammatory bile duct strictures, progressive …
Geniposide alleviated bile acid-associated NLRP3 inflammasome activation by regulating SIRT1/FXR signaling in bile duct ligation-induced liver fibrosis
T Qin, M Hasnat, Z Wang, HM Hassan, Y Zhou, Z Yuan… - Phytomedicine, 2023 - Elsevier
Background Geniposide (GE), the active compound derived from Gardeniae Fructus,
possesses valuable bioactivity for liver diseases, but GE effects on bile duct ligation (BDL) …
possesses valuable bioactivity for liver diseases, but GE effects on bile duct ligation (BDL) …